Geetha Puthenveetil
Pediatric Hematology-Oncology · Los Angeles, CANPI 1174626683
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $44,838 of the $62,221 with a category attached, or 72.1%. 19 manufacturers reported payments, led by Global Blood Therapeutics, Inc. at 25.4% of the total. Among pediatric hematology-oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $818.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Global Blood Therapeutics, Inc.$16K
- Vertex$12K
- Acceleron Pharma, Inc.$9K
- Chiesi USA, Inc.$9K
- AstraZeneca$6K
- Agios Pharmaceuticals, Inc.$6K
- plus $5K from 13 others
Across 51 payments — averaging $2547.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Global Blood Therapeutics, Inc.$52K
- Agios Pharmaceuticals, Inc.$33K
- AMAG Pharmaceuticals, Inc.$26K
- Novartis$13K
- AstraZeneca$5K
What the payments were for
- Consulting fees$44,83872%
- Speaking & faculty fees$12,69020%
- Travel & lodging$2,7254%
- Food & beverage$1,9283%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Global Blood Therapeutics, Inc. | 13 | $15,800 |
| Vertex | 12 | $12,424 |
| Acceleron Pharma, Inc. | 3 | $9,480 |
| Chiesi USA, Inc. | 8 | $8,501 |
| AstraZeneca | 14 | $5,847 |
| Agios Pharmaceuticals, Inc. | 1 | $5,507 |
| Novartis | 7 | $1,941 |
| Bristol Myers Squibb | 1 | $1,902 |
| Terumo BCT, Inc. | 2 | $240 |
| CSL Behring | 2 | $143 |
| Spark Therapeutics, Inc. | 2 | $123 |
| Pierre Fabre Pharmaceuticals, Inc. | 3 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Genentech USA, Inc. | 1 | $48 |
| Amgen | 1 | $37 |
| Mesoblast, Inc. | 1 | $32 |
| Eurofins Viracor, LLC | 1 | $29 |
| Bio Products Laboratory USA, Inc. | 1 | $23 |
| Medunik USA Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reblozyl$11,342
- OXBRYTA$10,865
- FERRIPROX$8,421
- PYRUKYND$5,507
- SOLIRIS$4,286
- ULTOMIRIS$1,252
- Spectra Optia$137
- Spectra Optia Apheresis System$103
How this compares
$62,221 in reported general payments places this provider in the 90th percentile of 307 pediatric hematology-oncology providers in California.
See all pediatric hematology-oncology providers in California →
Other pediatric hematology-oncology in Los Angeles
- Noah FedermanLos Angeles$399K
- Jan van TornoutLos Angeles$137K
- Thomas CoatesLos Angeles$99K
- Andrew DietzLos Angeles$88K
- Hisham Abdel AzimLos Angeles$52K
- Michael PulsipherLos Angeles$45K
- Leo MascarenhasLos Angeles$35K
- Edward GompertsLos Angeles$28K
- Paibel Aguayo-HiraldoLos Angeles$21K
- Paul GaynonLos Angeles$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.